Semaglutide 2.4 mg was approved for weight loss in individuals with obesity or overweight with weight-related health issues in July of 2021 under the commercial name Wegovy
10.1016/j.molmet.2017.08.010 [DOI] [PMC free article] [PubMed] [Google Scholar] 225.Courrges JP, Vilsbll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, et al
Nausea indicates that semaglutide is activating GLP-1 receptors in your stomach and brain, but it does not correlate with weight loss success
Lyophilized Powder: Preserved in air tight containers, protected from light (Recommended temperature: -25 ~ -15)
GLP-1 medications, originally used for those with Type 2 diabetes, have recently grown in popularity as a weight management tool with brand name drugs such as Ozempic, WeGovy and Byetta